Suppr超能文献

遗传性疾病和癌症分子病理学检测程序的临床应用谱:分子病理学协会报告

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.

作者信息

Joseph Loren, Cankovic Milena, Caughron Samuel, Chandra Pranil, Emmadi Rajyasree, Hagenkord Jill, Hallam Stephanie, Jewell Kay E, Klein Roger D, Pratt Victoria M, Rothberg Paul G, Temple-Smolkin Robyn L, Lyon Elaine

机构信息

Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Association for Molecular Pathology's Framework for the Evidence Needed to Demonstrate Clinical Utility Task Force, Bethesda, Maryland; Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, Michigan.

出版信息

J Mol Diagn. 2016 Sep;18(5):605-619. doi: 10.1016/j.jmoldx.2016.05.007. Epub 2016 Aug 16.

Abstract

Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the population tested or the purpose of the testing. This definition does not address all of the important applications of molecular diagnostic testing. Definitions consistent with a patient-centered approach emphasize and recognize that a clinical test result's utility depends on the context in which it is used and are particularly relevant to molecular diagnostic testing because of the nature of the information they provide. Debates surrounding levels and types of evidence needed to properly evaluate the clinical value of molecular diagnostics are increasingly important because the growing body of knowledge, stemming from the increase of genomic medicine, provides many new opportunities for molecular testing to improve health care. We address the challenges in defining the clinical utility of molecular diagnostics for inherited diseases or cancer and provide assessment recommendations. Starting with a modified analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications model for addressing clinical utility of molecular diagnostics with a variety of testing purposes, we recommend promotion of patient-centered definitions of clinical utility that appropriately recognize the valuable contribution of molecular diagnostic testing to improve patient care.

摘要

临床效用描述了每项实验室检查对该患者的益处。许多利益相关者对应用于肿瘤靶向药物治疗的分子检测的临床效用采用了狭义定义,而不考虑检测人群或检测目的。这一定义并未涵盖分子诊断检测的所有重要应用。以患者为中心的方法所采用的定义强调并认识到临床检测结果的效用取决于其使用背景,并且由于分子诊断检测所提供信息的性质,这些定义与分子诊断检测尤为相关。围绕正确评估分子诊断临床价值所需的证据水平和类型的辩论日益重要,因为随着基因组医学的发展,知识量不断增加,为分子检测改善医疗保健提供了许多新机会。我们探讨了在定义遗传性疾病或癌症分子诊断的临床效用方面所面临的挑战,并提供了评估建议。从一个经过修改的分析有效性、临床有效性、临床效用以及伦理、法律和社会影响模型开始,该模型用于处理具有各种检测目的的分子诊断的临床效用,我们建议推广以患者为中心的临床效用定义,这些定义应适当认识到分子诊断检测对改善患者护理的宝贵贡献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验